Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director · Chief Executive Officer | March 11, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date March 11, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,422,627 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Exercise / conversion · Acquired 139,387 · Balance 1,462,325 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2022-03-11 · Tax withholding · Disposed 39,698 · Balance 1,422,627 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 139,386 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Exercise / conversion · Disposed 139,387 · Balance 139,386 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Limited Partnership | 816,527 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 816,527 |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter: EK | 33,563 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 33,563 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK1 | 33,775 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,775 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,975 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,975 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK2 | 33,533 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 33,533 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2022 Filed Mar 14, 2022 20:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 139,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000020 · wf-form4_164728997772803.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,386 Underlying: Common Stock · 139,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 39,698 | $3.22 | $127,827.56 |
DisclosureSEC source: 0001055726-22-000020 · wf-form4_164728997772803.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,627 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 139,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000020 · wf-form4_164728997772803.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,462,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 63,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000016 · wf-form4_164686005009477.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 18,142 | $3.26 | $59,142.92 |
DisclosureSEC source: 0001055726-22-000016 · wf-form4_164686005009477.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322,938 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 63,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000016 · wf-form4_164686005009477.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 468,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000009 · wf-form4_164617791888639.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,500 Underlying: Common Stock · 468,500 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 468,500 restricted stock units is as follows: 156,167 shares will vest on February 26, 2023; 156,167 shares will vest on February 26, 2024; 156,166 shares will vest on February 26, 2025. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 468,500 restricted stock units is as follows: 156,167 shares will vest on February 26, 2023; 156,167 shares will vest on February 26, 2024; 156,166 shares will vest on February 26, 2025. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 468,500 restricted stock units is as follows: 156,167 shares will vest on February 26, 2023; 156,167 shares will vest on February 26, 2024; 156,166 shares will vest on February 26, 2025. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 468,500 restricted stock units is as follows: 156,167 shares will vest on February 26, 2023; 156,167 shares will vest on February 26, 2024; 156,166 shares will vest on February 26, 2025. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 627,700 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001055726-22-000009 · wf-form4_164617791888639.xml · derivative · entry 9 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,700 Underlying: Common Stock · 627,700 shares Expires 2032-02-26 F3 · derivative.exercise_date: The vesting schedule for the 627,700 options is as follows: 156,925 shares vested on February 26, 2022; 156,925 shares will vest on February 26, 2023; 156,925 shares will vest on February 26, 2024; 156,925 shares will vest on February 26, 2025. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 68,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000009 · wf-form4_164617791888639.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,533 Underlying: Common Stock · 68,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 20,045 | $3.22 | $64,544.90 |
DisclosureSEC source: 0001055726-22-000009 · wf-form4_164617791888639.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,277,380 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 68,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000009 · wf-form4_164617791888639.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:33 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 139,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000024 · wf-form4_161559198968115.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,773 Underlying: Common Stock · 139,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:33 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 74,545 | $10.57 | $787,940.65 |
DisclosureSEC source: 0001055726-21-000024 · wf-form4_161559198968115.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,658 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:33 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 139,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000024 · wf-form4_161559198968115.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 63,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,700 Underlying: Common Stock · 63,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 34,067 | $8.91 | $303,536.97 |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,816 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 63,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares vested on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 120,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares vested on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares vested on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares vested on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares vested on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 64,230 | $9.19 | $590,273.70 |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,134,183 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 120,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000022 · wf-form4_161533472915714.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,198,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares vested on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 206,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000013 · wf-form4_161438445356817.xml · derivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,300 Underlying: Common Stock · 206,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares will vest on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares will vest on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares will vest on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 319,800 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001055726-21-000013 · wf-form4_161438445356817.xml · derivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,800 Underlying: Common Stock · 319,800 shares Expires 2031-02-26 F1 · derivative.exercise_date: The vesting schedule for the 319,800 options is as follows: 79,950 shares vested on February 26, 2021; 79,950 shares will vest on February 26, 2022; 79,950 shares will vest on February 26, 2023; 79,950 shares will vest on February 26, 2024. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:14 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 62,500 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000008 · wf-form4_161239761257738.xml · derivative · entry 9 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2021-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:14 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 62,500 | $14.24 | $890,000.00 |
DisclosureSEC source: 0001055726-21-000008 · wf-form4_161239761257738.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,313 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $13.81 to $14.64, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:14 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 62,500 | $4.56 | $285,000.00 |
DisclosureSEC source: 0001055726-21-000008 · wf-form4_161239761257738.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,140,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 100,000 | $15.00 | $1,500,000.00 |
DisclosureSEC source: 0001055726-21-000008 · wf-form4_161239761257738.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,313 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000057 · wf-form4_160944854960637.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178,313 F1 · price: This transaction represents a charitable donation. This is not a market transaction, thus no price has been reported. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 23:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 100,000 | $21.13 | $2,113,450.00 |
DisclosureSEC source: 0001055726-20-000045 · wf-form4_159623712675309.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,188,313 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $20.19 to $22.78, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 418,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000017 · wf-form4_158404596759720.xml · derivative · entry 9 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,160 Underlying: Common Stock · 418,160 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares will vest on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares will vest on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares will vest on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 105,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000017 · wf-form4_158404596759720.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 36,826 | $5.70 | $209,908.20 |
DisclosureSEC source: 0001055726-20-000017 · wf-form4_158404596759720.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,288,313 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 105,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000017 · wf-form4_158404596759720.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 63,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,400 Underlying: Common Stock · 63,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 27,697 | $14.09 | $390,250.73 |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,439 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 63,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 120,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,100 Underlying: Common Stock · 120,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 37,371 | $9.80 | $366,235.80 |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183,436 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:18 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 120,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000008 · wf-form4_158378508254040.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| January 13, 2020 Filed Jan 13, 2020 17:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | PurchaseCommon Stock | 22,500 | $3.11 | $69,975.00 |
DisclosureSEC source: 0001055726-20-000002 · wf-form4_157893540555654.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,707 Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 13:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 296,705 | $2.31 | $684,735.80 |
DisclosureSEC source: 0001055726-19-000046 · wf-form4_155965320820052.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Limited Partnership Disclosed balance after: 816,527 F1 · kind: The sales reported in this Form 4 were made by a broker, without instruction by the reporting person, to satisfy a margin call by the broker, to whom these shares were pledged as collateral for a margin loan. F4 · price: These transactions were executed in multiple trades at prices ranging from $2.17 to $2.42, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 13:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 832,848 | $2.30 | $1,914,467.70 |
DisclosureSEC source: 0001055726-19-000046 · wf-form4_155965320820052.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,207 F1 · kind: The sales reported in this Form 4 were made by a broker, without instruction by the reporting person, to satisfy a margin call by the broker, to whom these shares were pledged as collateral for a margin loan. F3 · price: These transactions were executed in multiple trades at prices ranging from $2.15 to $2.41, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 13:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 500,000 | $2.40 | $1,200,800.00 |
DisclosureSEC source: 0001055726-19-000046 · wf-form4_155965320820052.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Limited Partnership Disclosed balance after: 1,113,232 F1 · kind: The sales reported in this Form 4 were made by a broker, without instruction by the reporting person, to satisfy a margin call by the broker, to whom these shares were pledged as collateral for a margin loan. F2 · price: These transactions were executed in multiple trades at prices ranging from $2.36 to $2.76, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 13:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 500,000 | $2.44 | $1,217,650.00 |
DisclosureSEC source: 0001055726-19-000046 · wf-form4_155965320820052.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,911,055 F1 · kind: The sales reported in this Form 4 were made by a broker, without instruction by the reporting person, to satisfy a margin call by the broker, to whom these shares were pledged as collateral for a margin loan. F2 · price: These transactions were executed in multiple trades at prices ranging from $2.36 to $2.76, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 21, 2019 Filed May 23, 2019 20:21 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 100,000 | $3.31 | $331,000.00 |
DisclosureSEC source: 0001055726-19-000044 · wf-form4_155864288064924.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411,055 F1 · kind: The sales reported in this Form 4 were made by a broker, without instruction by the reporting person, to satisfy a margin call by the broker, to whom these shares were pledged as collateral for a margin loan. F2 · price: These transactions were executed in multiple trades at prices ranging from $3.30 to $3.33, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 61,212 | $3.50 | $214,242.00 |
DisclosureSEC source: 0001055726-19-000042 · wf-form4_155812586719176.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Limited Partnership Disclosed balance after: 1,613,232 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $[3.50] to $[3.53], inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 75,556 | $3.50 | $264,446.00 |
DisclosureSEC source: 0001055726-19-000042 · wf-form4_155812586719176.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Limited Partnership Disclosed balance after: 1,674,444 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $[3.50] to $[3.53], inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 105,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,700 Underlying: Common Stock · 105,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 30,104 | $3.34 | $100,547.36 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511,055 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units award reported in footnote (3) herein. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 105,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,541,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares vested on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 57,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units was as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares vested on March 9, 2019. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units was as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares vested on March 9, 2019. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units was as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares vested on March 9, 2019. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units was as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares vested on March 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.